{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:44:03Z","timestamp":1790009043646,"version":"4.0.1"},"reference-count":72,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2018.6125","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T11:15:04Z","timestamp":1545390904000},"page":"e186125","source":"Crossref","is-referenced-by-count":80,"title":["Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes"],"prefix":"10.1001","volume":"1","author":[{"given":"Matthew J.","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Karam","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amisha","family":"Wallia","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H.","family":"Kang","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lancki","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Moran","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Now with Oak Street Health, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Liss","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Prospect","sequence":"additional","affiliation":[{"name":"Enterprise Research and Development, UnitedHealth Group, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald T.","family":"Ackermann","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"issue":"9","key":"zoi180259r1","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2337\/dc12-0002","article-title":"Diabetes and cause-specific mortality in a prospective cohort of one million US adults.","volume":"35","author":"Campbell","year":"2012","journal-title":"Diabetes Care"},{"key":"zoi180259r2","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142018.","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"zoi180259r3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","article-title":"Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data.","volume":"27","author":"Nesti","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"zoi180259r4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142018 executive summary.","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"issue":"14","key":"zoi180259r5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi180259r6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi180259r7","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2337\/dc16-0303","article-title":"Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial.","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi180259r8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi180259r9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi180259r10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi180259r11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi180259r12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi180259r13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi180259r14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"zoi180259r15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s11606-017-4061-7","article-title":"Shifting paradigms in the medical management of type 2 diabetes: reflections on recent cardiovascular outcome trials.","volume":"32","author":"Ismail-Beigi","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"4","key":"zoi180259r18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"zoi180259r20","doi-asserted-by":"publisher","first-page":"e000421","DOI":"10.1136\/bmjdrc-2017-000421","article-title":"Correlates of second-line type 2 diabetes medication selection in the USA.","volume":"5","author":"Ackermann","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"zoi180259r21","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"issue":"5","key":"zoi180259r22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/jamia\/ocv054","article-title":"An algorithm to identify medication nonpersistence using electronic pharmacy databases.","volume":"22","author":"Parker","year":"2015","journal-title":"J Am Med Inform Assoc"},{"issue":"5","key":"zoi180259r23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors.","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care"},{"issue":"11","key":"zoi180259r24","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2215\/CJN.03900416","article-title":"Use of electronic health data to estimate heart failure events in a population-based cohort with CKD.","volume":"11","author":"Floyd","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"zoi180259r25","doi-asserted-by":"publisher","first-page":"e000206","DOI":"10.1136\/bmjdrc-2016-000206","article-title":"Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy.","volume":"4","author":"Korytkowski","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"zoi180259r26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals.","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"6","key":"zoi180259r27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0021-9681(82)90058-3","article-title":"Adjusted survival curve estimation using covariates.","volume":"35","author":"Makuch","year":"1982","journal-title":"J Chronic Dis"},{"issue":"2","key":"zoi180259r28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model.","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed"},{"issue":"12","key":"zoi180259r29","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1001\/jamainternmed.2014.5294","article-title":"Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.","volume":"174","author":"Berkowitz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"4","key":"zoi180259r30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.amepre.2016.02.023","article-title":"Trends in the prevalence of coronary heart disease in the US: National Health and Nutrition Examination Survey, 2001-2012.","volume":"51","author":"Yoon","year":"2016","journal-title":"Am J Prev Med"},{"issue":"4","key":"zoi180259r31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/cd16-0005","article-title":"More than 7 years of hindsight: revisiting the FDA\u2019s 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications.","volume":"34","author":"Regier","year":"2016","journal-title":"Clin Diabetes"},{"issue":"1","key":"zoi180259r33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/ajp.156.1.5","article-title":"Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research.","volume":"156","author":"Wells","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"8","key":"zoi180259r34","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.2337\/dc13-1221","article-title":"Comparative effectiveness and the future of clinical research in diabetes.","volume":"36","author":"Greenfield","year":"2013","journal-title":"Diabetes Care"},{"key":"zoi180259r35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/dom.2018.20.issue-S1","article-title":"What have we learnt from \u201creal world\u201d data, observational studies, and meta-analyses.","volume":"20","author":"Chatterjee","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"zoi180259r36","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.2337\/dc13-0356","article-title":"Rationale and design of the Glycemia Reduction Approaches in Diabetes: a comparative effectiveness study (GRADE).","volume":"36","author":"Nathan","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"zoi180259r37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"zoi180259r38","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/dom.2017.19.issue-11","article-title":"Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.","volume":"19","author":"Zimmerman","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"zoi180259r39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"zoi180259r40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/dom.12889","article-title":"Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.","volume":"19","author":"Nystr\u00f6m","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"zoi180259r41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"zoi180259r42","doi-asserted-by":"publisher","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"zoi180259r43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the US: real-world evidence in patients newly diagnosed with type 2 diabetes.","volume":"41","author":"Montvida","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"zoi180259r44","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies.","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"issue":"22","key":"zoi180259r45","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1001\/jama.2014.5951","article-title":"Insulin therapy for type 2 diabetes mellitus.","volume":"311","author":"Wallia","year":"2014","journal-title":"JAMA"},{"key":"zoi180259r46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13098-017-0237-x","article-title":"Basal hyperinsulinemia beyond a threshold predicts major adverse cardiac events at 1 year after coronary angiogram in type 2 diabetes mellitus: a retrospective cohort study.","volume":"9","author":"Srinivasan","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"zoi180259r47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1210\/er.2005-0007","article-title":"Insulin resistance and atherosclerosis.","volume":"27","author":"Nigro","year":"2006","journal-title":"Endocr Rev"},{"issue":"5","key":"zoi180259r48","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.2337\/dc10-1915","article-title":"Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes.","volume":"34","author":"Johnston","year":"2011","journal-title":"Diabetes Care"},{"issue":"9681","key":"zoi180259r49","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a multicentre, randomised, open-label trial.","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"issue":"9493","key":"zoi180259r50","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial.","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"zoi180259r51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"issue":"14","key":"zoi180259r52","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch Intern Med"},{"issue":"14","key":"zoi180259r53","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack.","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"9131","key":"zoi180259r54","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"9131","key":"zoi180259r55","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"22","key":"zoi180259r56","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1001\/jama.2014.4312","article-title":"Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.","volume":"311","author":"Roumie","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"zoi180259r57","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"zoi180259r58","doi-asserted-by":"publisher","first-page":"4817178","DOI":"10.1155\/2018\/4817178","article-title":"Treatment discontinuation and clinical events in type 2 diabetes patients treated with dipeptidyl peptidase-4 inhibitors or NPH insulin as third-line therapy.","volume":"2018","author":"Moura","year":"2018","journal-title":"J Diabetes Res"},{"issue":"3","key":"zoi180259r59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00592-014-0692-x","article-title":"Persistence and adherence to oral antidiabetics: a population-based cohort study.","volume":"52","author":"Simard","year":"2015","journal-title":"Acta Diabetol"},{"issue":"4","key":"zoi180259r60","doi-asserted-by":"publisher","first-page":"e181755","DOI":"10.1001\/jamanetworkopen.2018.1755","article-title":"Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the Observational Health Data Sciences and Informatics Initiative.","volume":"1","author":"Vashisht","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi180259r61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"issue":"19","key":"zoi180259r62","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"4","key":"zoi180259r63","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1475-6773.2007.00822.x","article-title":"Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database.","volume":"43","author":"Quan","year":"2008","journal-title":"Health Serv Res"},{"issue":"4","key":"zoi180259r64","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc16-0985","article-title":"Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013.","volume":"40","author":"Lipska","year":"2017","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi180259r65","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2337\/dc17-0291","article-title":"Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials.","volume":"40","author":"Kaul","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"zoi180259r66","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study.","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"zoi180259r67","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"zoi180259r68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2337\/dc16-1580","article-title":"Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study.","volume":"40","author":"Kumarathurai","year":"2017","journal-title":"Diabetes Care"},{"issue":"10","key":"zoi180259r69","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/dme.2013.30.issue-10","article-title":"Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis.","volume":"30","author":"Phung","year":"2013","journal-title":"Diabet Med"},{"issue":"2","key":"zoi180259r70","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/dc14-0920","article-title":"Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.","volume":"38","author":"Khunti","year":"2015","journal-title":"Diabetes Care"},{"issue":"23","key":"zoi180259r71","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study.","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"zoi180259r72","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00125-014-3369-7","article-title":"Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes.","volume":"57","author":"Zoungas","year":"2014","journal-title":"Diabetologia"},{"key":"zoi180259r16","volume-title":"Criteria for Distinguishing Effectiveness From Efficacy Trials in Systematic Reviews","author":"Gartlehner","year":"2006"},{"key":"zoi180259r17","volume-title":"Initial National Priorities for Comparative Effectiveness Research","author":"Institute of Medicine","year":"2009"},{"key":"zoi180259r19","volume-title":"ICD-9-CM Official Guidelines for Coding and Reporting","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"zoi180259r32","volume-title":"Guidance for Industry Diabetes Mellitus\u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","author":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)","year":"2008"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2719133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T12:38:38Z","timestamp":1549888718000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2018.6125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6125","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,21]]}}}